11/11/11 In a move that will advance the Kanzius Noninvasive Radiowave Cancer Treatment closer to the FDA approval and the human clinical trials phase, the Kanzius Cancer Research Foundation has awarded a grant totaling $182,725 to The University of Texas M.D. Anderson Cancer Center and Dr. Steven Curley, lead researcher at the Curley/Kanzius Lab in Houston, Texas. Dr. Curley applied for the grant, citing the need for new analytical equipment to produce data that he declared “critical” to an FDA application.
This grant award comes on the heels of a positive visit from the National Cancer Institute (NCI) to Dr. Curley’s lab last week. NCI examiners toured the lab for the second time since being awarded a $2.4 million NCI U54 grant in 2009, and declared the Kanzius Noninvasive Radiowave Cancer Treatment to be “exciting and very promising.”
“We are extremely pleased that Dr. Curley’s work is being recognized in such a positive and important way,” said Mark A. Neidig, Sr., Executive Director of the Kanzius Cancer Research Foundation. “In approving this grant and providing funding to Dr. Curley and the Kanzius research team, this will allow future outcomes data, like that which was recently praised by the NCI, to be included in a compelling application to the FDA. This process will be directed by ThermMed LLC, the developers of the Kanzius RF device and treatment.”
About Kanzius Cancer Research Foundation:
Kanzius Cancer Research Foundation is a non-profit organization dedicated to funding research for the Kanzius Noninvasive Radiowave Treatment project, the world’s most promising cancer treatment. With ongoing studies at two of the world’s premiere cancer research institutions; this treatment uses targeted nanoparticles and radiowaves to effectively kill cancer cells without harmful side effects. Preliminary studies have been validated in more than 15 medical journals and with additional funding; KCRF can help accelerate the speed at which this treatment becomes available to cancer patients. For more information about Kanzius Cancer Research Foundation, please visit www.kanzius.org.
